Bayer CropScience Tidigare resultatutveckling
Tidigare kriterier kontrolleras 6/6
Bayer CropScience har ökat intäkterna med en genomsnittlig årlig takt på 3.7%, medan Chemicals -branschen såg intäkterna växer på 6.7% årligen. Intäkterna har varit växande med en genomsnittlig takt på 5.5% per år. Bayer CropScience s avkastning på eget kapital är 21.5% och den har en nettomarginal på 11.9%.
Viktig information
3.72%
Tillväxttakt i vinsten
3.72%
Tillväxttakt för EPS
| Chemicals Tillväxt i branschen | 17.68% |
| Intäkternas tillväxttakt | 5.45% |
| Avkastning på eget kapital | 21.46% |
| Nettomarginal | 11.93% |
| Nästa resultatuppdatering | 26 May 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
506285: Stable Assumptions And Upcoming Results Will Shape A Balanced Outlook
Analysts have maintained their fair value estimate for Bayer CropScience at ₹5,209.63 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin and future P/E. This suggests that their overall view on the stock's long-term potential remains broadly unchanged.506285: Upcoming Results And Refined Assumptions Will Support A Balanced Outlook
The analyst price target for Bayer CropScience has been adjusted slightly higher to ₹5,209.63 from ₹5,187.13. Analysts point to updated fair value estimates, a modest change in the assumed discount rate, and revised expectations for revenue, profit margins, and future P/E as key inputs behind this move.506285: Upcoming Results And Stable Assumptions Will Support A Balanced Outlook
Analysts have kept their price target on Bayer CropScience broadly unchanged around ₹5,187. This reflects only marginal model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.506285: Upcoming Results And Stable Assumptions Will Support A Positive Outlook
Analysts have marginally revised their price target for Bayer CropScience to ₹5,187, reflecting small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in the outlook. What's in the News A board meeting is scheduled for February 11, 2026, to review and consider the unaudited financial results for the quarter ended December 31, 2025 (Key Developments).506285: Sustainability Partnership And Upcoming Results Will Support A Positive Outlook
Analysts have kept their price target for Bayer CropScience broadly unchanged around ₹5,187, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).506285: Sustainability Collaboration And Upcoming Results Will Support A Balanced Outlook
Analysts have trimmed their price target for Bayer CropScience to ₹5,187 from about ₹5,278, reflecting updated views on slightly lower fair value, a modestly adjusted discount rate, marginally different margin expectations and a revised future P/E assumption, while keeping revenue growth assumptions largely supportive. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).506285: Expanded Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience effectively unchanged at €5,277.67, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects steady underlying expectations rather than a shift in view.506285: Farmer Focused Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have slightly reduced their fair value estimate for Bayer CropScience to about €5,278. This reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, without a major shift in the overall thesis.506285: Interim Dividend Decision Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience steady, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding a largely unchanged price target narrative. What's in the News A board meeting is scheduled for November 7, 2025, to review the unaudited financial results for the quarter ended September 30, 2025.506285: Interim Dividend Decision Will Drive Bullish Momentum Into Next Year
Analysts have modestly raised their price target on Bayer CropScience by about €5, citing a slightly higher long term discount rate and valuation assumptions that leave fair value largely unchanged. What's in the News Board meeting scheduled for November 7, 2025, to review unaudited financial results for the quarter ended September 30, 2025 (Key Developments) Board to consider declaration of an interim dividend for the financial year 2025 to 2026 at the November 7, 2025 meeting (Key Developments) Record date for the proposed interim dividend to be fixed during the upcoming board meeting (Key Developments) Valuation Changes The discount rate has risen slightly from 13.34% to 13.35%, reflecting a marginally higher required return on equity.506285: Interim Dividend Decision Will Drive Bullish Sentiment Into 2025
Narrative Update on Bayer CropScience Analysts have trimmed their price target for Bayer CropScience by approximately EUR 275, reflecting slightly softer expectations for revenue growth and profit margins, even as long term valuation multiples remain supportive. What's in the News A board meeting is scheduled for November 7, 2025 to review the unaudited financial results for the quarter ended September 30, 2025.506285: Interim Dividend Consideration Will Drive Bullish Momentum Into 2025
Narrative Update on Bayer CropScience Analysts have lowered their fair value estimate for Bayer CropScience from €5,939 to €5,556. They attribute this reduction to a slightly lower projected profit margin, which outweighs improvements in expected revenue growth and a modest decrease in the discount rate.Seeds, Traits And Biofuels Will Unlock New Value Pools
Strategic cost reductions and efficiency improvements are expected to enhance net margins and unlock substantial additional cash.Fördelning av intäkter och kostnader
Hur Bayer CropScience tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Dec 25 | 56,206 | 6,704 | 7,462 | 0 |
| 30 Sep 25 | 55,718 | 6,089 | 7,540 | 0 |
| 30 Jun 25 | 57,566 | 5,925 | 7,574 | 0 |
| 31 Mar 25 | 54,734 | 5,680 | 7,527 | 0 |
| 31 Dec 24 | 52,172 | 5,207 | 7,208 | 0 |
| 30 Sep 24 | 51,152 | 5,796 | 7,116 | 0 |
| 30 Jun 24 | 49,948 | 6,662 | 6,965 | 0 |
| 31 Mar 24 | 51,062 | 7,405 | 6,902 | 0 |
| 31 Dec 23 | 52,942 | 8,030 | 7,684 | 0 |
| 30 Sep 23 | 53,772 | 8,444 | 8,020 | 0 |
| 30 Jun 23 | 52,119 | 7,841 | 8,299 | 0 |
| 31 Mar 23 | 51,397 | 7,582 | 8,616 | 0 |
| 31 Dec 22 | 51,205 | 7,524 | 8,381 | 0 |
| 30 Sep 22 | 50,727 | 7,027 | 8,313 | 0 |
| 30 Jun 22 | 49,859 | 6,942 | 8,027 | 0 |
| 31 Mar 22 | 47,344 | 6,453 | 7,836 | 0 |
| 31 Dec 21 | 45,048 | 5,545 | 6,549 | 0 |
| 30 Sep 21 | 44,329 | 4,246 | 6,090 | 0 |
| 30 Jun 21 | 44,494 | 4,951 | 5,858 | 0 |
| 31 Mar 21 | 42,613 | 4,931 | 5,726 | 0 |
| 31 Dec 20 | 39,913 | 4,627 | 5,706 | 0 |
| 30 Sep 20 | 39,271 | 6,457 | 5,559 | 0 |
| 30 Jun 20 | 38,918 | 5,909 | 5,703 | 0 |
| 31 Mar 20 | 36,094 | 4,745 | 5,729 | 0 |
| 31 Dec 19 | 29,294 | 2,864 | 5,437 | 0 |
| 30 Sep 19 | 28,505 | 2,116 | 5,580 | 0 |
| 30 Jun 19 | 25,256 | 1,497 | 5,427 | 0 |
| 31 Mar 19 | 31,754 | 3,371 | 6,010 | 0 |
| 31 Dec 18 | 28,639 | 3,045 | 4,621 | 0 |
| 30 Sep 18 | 27,226 | 2,877 | 4,476 | 0 |
| 30 Jun 18 | 28,505 | 3,356 | 4,392 | 0 |
| 31 Mar 18 | 27,167 | 3,001 | 4,327 | 0 |
| 31 Dec 17 | 26,375 | 2,769 | 4,280 | 0 |
| 30 Sep 17 | 28,203 | 3,030 | 4,242 | 0 |
| 30 Jun 17 | 26,796 | 2,715 | 2,507 | 0 |
| 31 Mar 17 | 28,153 | 2,910 | 4,129 | 0 |
| 31 Dec 16 | 40,105 | 3,323 | 4,219 | 0 |
| 30 Sep 16 | 32,030 | 3,342 | 3,519 | 0 |
| 30 Jun 16 | 38,027 | 3,215 | 4,116 | 0 |
| 31 Mar 16 | 27,838 | 3,151 | 4,073 | 0 |
| 31 Dec 15 | 37,919 | 3,278 | 6,458 | 0 |
| 30 Sep 15 | 38,569 | 3,554 | 6,469 | 0 |
| 30 Jun 15 | 39,222 | 3,814 | 6,433 | 0 |
Kvalitetsintäkter: 506285 har inkomster av hög kvalitet.
Växande vinstmarginal: 506285 s nuvarande netto vinstmarginaler (11.9%) är högre än förra året (10%).
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: 506285 s intäkter har ökat med 3.7% per år under de senaste 5 åren.
Accelererande tillväxt: 506285 s intäktstillväxt under det senaste året ( 28.7% ) överstiger sitt 5-åriga genomsnitt ( 3.7% per år).
Resultat vs industri: 506285 vinsttillväxt under det senaste året ( 28.7% ) översteg Chemicals branschen 10.4%.
Avkastning på eget kapital
Hög ROE: 506285 s avkastning på eget kapital ( 21.5% ) anses vara hög.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/21 03:48 |
| Aktiekurs vid dagens slut | 2026/05/21 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Bayer CropScience Limited bevakas av 26 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Himanshu Binani | Anand Rathi Shares and Stock Brokers Limited |